Evoke surges on positive study for nasal spray

Evoke Pharma

28/10/2024 11:56

** Shares of drug developer Evoke Pharma  EVOK.O  more than
double to $12.56 premarket
    ** Co says Gimoti, the nasal spray version of drug
metoclopramide, when given to patients on GLP-1 weight loss
treatments showed better reduction in symptoms compared to the
oral version of metoclopramide
    ** EVOK says Gimoti can be used to treat patients on GLP-1
drugs with gastroparesis, a medical condition that prevents the
stomach from emptying food and liquids properly
    ** Up to last close, stock down 58% YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))